Sandoz and mAbxience partner on global emicizumab biosimilar programme
Sandoz and mAbxience have entered a global collaboration to develop, manufacture and commercialise a proposed biosimilar to Roche's haemophilia medicine Hemlibra.
mAbxience will lead development and manufacturing of the emicizumab biosimilar, while Sandoz will hold exclusive commercialisation rights across most global markets.
The agreement expands both companies' biosimilar portfolios and targets a major biologic franchise with estimated annual global sales of approximately $5.7 billion.
Field | Content |
Alert Type | Deal |
Companies | Sandoz; mAbxience |
Deal Type | Biosimilar development, manufacturing and commercialisation agreement |
Asset or Company | Proposed emicizumab biosimilar |
Reference Product | Hemlibra |
Therapy Area(s) | Haematology; haemophilia A |
Technology or Modality | Biosimilar monoclonal antibody |
Reference Product Sales | Approximately US$5.7 billion in annual global sales |
Deal Value | Financial terms were not disclosed |
Geography | Most global markets |
What Happened | Sandoz and mAbxience entered an agreement covering development, manufacturing and commercialisation of a proposed emicizumab biosimilar referencing Hemlibra. |
Why It Matters | The partnership targets a major haemophilia biologic and adds another high-value programme to the global biosimilar pipeline. |
Supporting Context | mAbxience will lead development and manufacturing while Sandoz will be responsible for commercialisation across most markets. |
Strategic Rationale | The companies combine mAbxience's development and production capabilities with Sandoz's global biosimilar commercial infrastructure. |
Potential Impact | A successfully approved biosimilar could increase competition and expand access to emicizumab treatment for people with haemophilia A. |
Key Takeaway | Sandoz and mAbxience are partnering globally on a proposed biosimilar to Hemlibra. |
What to Watch | Clinical development, regulatory submissions and future market-entry timing relative to Hemlibra's exclusivity landscape. |
Primary Source | mAbxience / Sandoz |
Relevant Date | 21 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare